HUMAX Trademark
HUMAX is a USPTO trademark filed by Genmab A/S. Status: Registered.
Prosecution Summary
Trademark Summary
HUMAX is a standard-character word mark covering biochemicals, specifically monoclonal antibodies for in vitro or scientific research regarding cancer, acquired immune deficiency syndrome (AIDS), other infectious diseases, autoimmune diseases, and cardiovascular diseases (Class 001), and monoclonal antibody therapeutic pharmaceuticals for use in the treatment of cancer, AIDS, other infectious diseases, autoimmune diseases, and cardiovascular diseases (Class 005). The registration is currently active, with the USPTO indicating that the registration has been renewed as of February 5, 2026. The owner is Genmab A/S. No active opposition or other legal proceedings are listed.
Recent Activity
Key recent milestone entries include acceptance o
Trademark Facts
| Mark | HUMAX |
|---|---|
| Serial Number | 76123326 |
| Registration Number | 2948397 |
| Status | Registered |
| Filing Date | 2000-09-06 |
| Registration Date | 2005-05-10 |
| Mark Type | Word |
| Nice Classes | 001 (Chemicals), 005 (Pharmaceuticals) |
| Owner | Genmab A/S |
| Attorney of Record | Max Vern |
| Prosecution Events | 64 |
| Latest Event | RNL2 on 2026-02-05 |
Goods & Services
Class 001: biochemicals; namely, monoclonal antibodies for in vitro or scientific research regarding cancer [, acquired immune deficiency syndrome (AIDS), and other infectious diseases, autoimmune diseases, and cardiovascular diseases ]; Class 005: monoclonal antibody therapeutic pharmaceuticals for use in the treatment of cancer [, acquired immune deficiency syndrome (AIDS), and other infectious diseases, autoimmune diseases, and cardiovascular diseases ]